Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | KCNK2 | O95069 | 4/20 | 0.32 |
| ▸ | KCNK10 | P57789 | 3/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149970 | 0.90 | RXFP1 (0.35) | BRAFKCNK2KCNK10RXFP1HTT | |
| SCHEMBL4145160 | 0.89 | RXFP1 (0.37) | BRAFKCNK2KCNK10RXFP1HTT | |
| SCHEMBL5311662 | 0.88 | BRAF (0.33) | BRAFKCNK2RXFP1HTT | |
| SCHEMBL4141961 | 0.86 | PPARG (0.37) | BRAFKCNK2KCNK10RXFP1 | |
| SCHEMBL5313986 | 0.83 | HTT (0.36) | BRAFKCNK2KCNK10RXFP1HTT | |
| SCHEMBL4145098 | 0.81 | RORC (0.33) | — | |
| SCHEMBL4636378 | 0.80 | RXFP1 (0.37) | BRAFKCNK2KCNK10RXFP1 | |
| SCHEMBL5316114 | 0.80 | KMT2A (0.35) | BRAFKCNK2KCNK10RXFP1HTT | |
| SCHEMBL5316133 | 0.80 | POLB (0.39) | KCNK2KCNK10RXFP1 | |
| SCHEMBL5335591 | 0.79 | HTT (0.34) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1937629-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007046513-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007046513-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | BTK, BRIX1, NFXL1 | BRAF 40/4885KCNK2 1003/4885KCNK10 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.